FOGHORN THERAPEUTICS INC (FHTX)
US3441741077 - Common Stock
FHTX Makes Notable Cross Below Critical Moving Average
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated...
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Company presentation and fireside chat on April 11th at 11:45 a.m. ET
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Company presentation and fireside chat on April 11th at 11:45 a.m. ET...
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909...
FHTX Crosses Below Key Moving Average Level
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative...
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Foghorn Therapeutics (NASDAQ:FHTX) just reported results for the fourth quarter...
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a...
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of...
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn stock gains as Eli Lilly picks lung cancer drug (NASDAQ:FHTX)
A collaboration between Eli Lilly (LLY) and Foghorn Therapeutics (FHTX) leads to a potential lung cancer therapeutic. Read more here.
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture,...
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
Flagship Pioneering Debuts Enabling Technologies Initiative
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced the formation of a new strategic initiative to foster enabling...
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge...
Foghorn Therapeutics announces CFO departure (NASDAQ:FHTX)
Foghorn Therapeutics announces departure of CFO Allan Reine and begins search for successor.
Foghorn Therapeutics Announces CFO Departure
Foghorn Therapeutics Announces CFO Departure
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in...
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study...
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
First patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024Transitioned the BRM Selective inhibitor program to...
Flagship Pioneering Launches Pioneering Intelligence
/PRNewswire/ -- Flagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to...
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...